Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

3.065 +0.305 (+11.05%)

Streaming Delayed Price Updated: 9:41 AM EDT, Jun 17, 2026 Add to My Watchlist

Price and Volume

Volume	8,032,233
Open	3.155
Bid (Size)	3.050 (500)
Ask (Size)	3.080 (200)
Prev. Close	2.760
Today's Range	2.860 - 3.200
52wk Range	2.660 - 16.00
Shares Outstanding	29,798,399
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer

Today 8:00 EDT

From Elicio Therapeutics Inc.

Via GlobeNewswire

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗

June 16, 2026

Via Chartmill

Performance

YTD	-61.9%	-61.9%
1 Month	-68.0%	-68.0%
3 Month	-74.8%	-74.8%
6 Month	-62.4%	-62.4%
1 Year	-60.2%	-60.2%

More News

Monday's session: top gainers and losers ↗

June 15, 2026

Via Chartmill

Gapping stocks in Monday's session ↗

June 15, 2026

Via Chartmill

Elicio Therapeutics (NASDAQ:ELTX) Q1 2026 Results Show Extended Cash Runway Ahead of Key Phase 2 Data Readout ↗

May 11, 2026

Via Chartmill

Monday's pre-market session: top gainers and losers ↗

June 15, 2026

Via Chartmill

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer

June 15, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology

June 01, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 11, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics to Present at the Bank of America Healthcare Conference

April 30, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

April 16, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

March 17, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

March 12, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

February 25, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

February 18, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

January 16, 2026

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

December 16, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

December 11, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

November 19, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

November 07, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

November 03, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

October 27, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

September 29, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Elicio Therapeutics Reports Inducement Grants

September 18, 2025

From Elicio Therapeutics Inc.

Via GlobeNewswire

Frequently Asked Questions

Is Elicio Therapeutics, Inc. - Common Stock publicly traded?

Yes, Elicio Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Elicio Therapeutics, Inc. - Common Stock trade on?

Elicio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Elicio Therapeutics, Inc. - Common Stock?

The ticker symbol for Elicio Therapeutics, Inc. - Common Stock is ELTX on the Nasdaq Stock Market

What is the current price of Elicio Therapeutics, Inc. - Common Stock?

The current price of Elicio Therapeutics, Inc. - Common Stock is 3.065

When was Elicio Therapeutics, Inc. - Common Stock last traded?

The last trade of Elicio Therapeutics, Inc. - Common Stock was at 06/17/26 09:41 AM ET

What is the market capitalization of Elicio Therapeutics, Inc. - Common Stock?

The market capitalization of Elicio Therapeutics, Inc. - Common Stock is 91.33M

How many shares of Elicio Therapeutics, Inc. - Common Stock are outstanding?

Elicio Therapeutics, Inc. - Common Stock has 91M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.